Treatment of Huntington's Disease

Neurotherapeutics

Volumn 11, Issue 1, 2014, Pages 153-160

  Frank, Samuel ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CAG repeat disorders; Chorea; Huntington's disease; Movement disorders; Subcortical dementia; Tetrabenazine

Indexed keywords

4 AMINOBUTYRIC ACID; ARIPIPRAZOLE; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER; OLANZAPINE; TETRABENAZINE;

BEHAVIOR DISORDER; BRAIN DEGENERATION; CHOREA; DRUG EFFICACY; FAMILY HISTORY; HUMAN; HUNTINGTON CHOREA; MENTAL DISEASE; MOTOR PERFORMANCE; PARKINSONISM; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR;

ADRENERGIC UPTAKE INHIBITORS; HUMANS; HUNTINGTON DISEASE; TETRABENAZINE;

EID: 84893118401     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0244-z     Document Type: Review

References (112)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72: 971-983.
2. Nucifora FC Jr, Sasaki M, Peters MF, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001;291: 2423-2428.
3. Subramaniam S, Sixt KM, Barrow R, Snyder SH. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009;324: 1327-1330.
4. Ribeiro FM, Paquet M, Ferreira LT, et al. Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease. J Neurosci 2010;30: 316-324.
5. Andrich J, Saft C, Ostholt N, Müller T. Complex movement behavior and progression of Huntington's disease. Neurosci Lett 2007;416: 272-274.
6. Frank S, Marshall F, Plumb S, et al. Functional decline due to chorea in Huntington's disease. Neurology 2004;62(Suppl. 5): A204.
7. Verhagen ML, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002;59: 694-699.
8. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003;361: 1642-1644.
9. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431: 805-810.
10. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000;97: 505-519.
11. Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 1992;31: 425-430.
12. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 1988;85: 5733-5737.
13. Mitchell IJ, Cooper AJ, Griffiths MR. The selective vulnerability of striatopallidal neurons. Prog Neurobiol 1999;59: 691-719.
14. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119: 2085-2095.
15. Augood SJ, Faull RL, Emson PC. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 1997;42: 215-221.
16. Feigin A, Tang C, Ma Y, et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007;130: 2858-2867.
17. Andrews TC, Weeks RA, Turjanski N, et al. Huntington's disease progression. PET and clinical observations. Brain 1999;122: 2353-2363.
18. Weeks RA, Piccini P, Harding AE, et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 1996;40: 49-54.
19. Cha JH, Kosinski CM, Kerner JA, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A 1998;95: 6480-6485.
20. Perry TL, Hansen S, Kloster M. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N Engl J Med 1973;288: 337-342.
21. Paulsen JS. Functional imaging in Huntington's disease. Exp Neurol 2009;216: 272-277.
22. Gourfinkel-An I, Parain K, Hartmann A, et al. Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice. J Neurochem 2003;86: 1369-1378.
23. Nicniocaill B, Haraldsson B, Hansson O, et al. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur J Neurosci 2001;13: 206-210.
24. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004;20: 146-154.
25. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001;292: 1552-1555.
26. Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002;11: 1107-1117.
27. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci 2000;23: 387-392.
28. Cepeda C, Hurst RS, Calvert CR, et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 2003;23: 961-969.
29. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 1991;18: 492-498.
30. Gunawardena S, Goldstein LS. Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol 2005;62: 46-51.
31. Harper PS. The epidemiology of Huntington's disease. Hum Genet 1992;89: 365-376.
32. Morrison PJ, Johnston WP, Nevin NC. The epidemiology of Huntington's disease in Northern Ireland. J Med Genet 1995;32: 524-530.
33. Peterlin B, Kobal J, Teran N, et al. Epidemiology of Huntington's disease in Slovenia. Acta Neurol Scand 2009;119: 371-375.
34. Alonso ME, Ochoa A, Boll MC, et al. Clinical and genetic characteristics of Mexican Huntington's disease patients. Mov Disord 2009;24: 2012-2015.
35. Simpson SA, Johnston AW. The prevalence and patterns of care of Huntington's chorea in Grampian. Br J Psychiatry 1989;155: 799-804.
36. Penney JB Jr, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5: 93-99.
37. Harper PS. The epidemiology of Huntington's disease. In: Bates G, Harper P, Jones L, eds. Huntington's disease. 3rd ed. Oxford Monographs on Medical Genetics, 2002.
38. Ribai P, Nguyen K, Hahn-Barma V, et al. Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients. Arch Neurol 2007;64: 813-819.
39. Di ML, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM. Suicide risk in Huntington's disease. J Med Genet 1993;30: 293-295.
40. Pollard J. Hurry up and wait: a cognitive care companion. 9/25/08. XX, Lulu Press, US, 2008. http://www. lulu. com/shop/james-pollard/hurry-up-and-wait/paperback/product-3610588. html#productDetails.
41. Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006;67: 1268-1271.
42. de Tommaso M, Difruscolo O, Sciruicchio V, Specchio N, Livrea P. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol 2007;30: 43-46.
43. Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol 2009;29: 484-487.
44. Paulsen Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 2011;11: 474-483.
45. Pidgeon C, Rickards H. The pathophysiology and pharmacological treatment of Huntington disease. Behav Neurol 2013;26: 245-253.
46. Armstrong MJ, Miyasaki JM; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012;79: 597-603.
47. Paleacu D. Tetrabenazine in the treatment of Huntington's Disease. Neuropsychiatr Dis Treat 2007;3: 545-551.
48. Bagchi SP. Differential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamine. Biochem Pharmacol 1983;32: 2851-2856.
49. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008;5: 181-197.
50. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008;23: 1491-1504.
51. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 2008;21: 497-503.
52. Imarisio S, Carmichael J, Korolchuk V, et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 2008;412: 191-209.
53. Walker FO. Huntington's disease. Lancet 2007;369: 218-228.
54. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009;8: 844-856.
55. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006;12: 2701-2720.
56. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Sys Rev 2009: CD006456.
57. Nakamura K, Aminoff MJ. Huntington's disease: clinical characteristics, pathogenesis and therapies. Drugs Today (Barc) 2007;43: 97-116.
58. Handley OJ, Naji JJ, Dunnett SB, Rosser AE. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin Sci (Lond) 2006;110: 73-88.
59. Bonelli RM, Hofmann P. A review of the treatment options for Huntington's disease. Expert Opin Pharmacother 2004;5: 767-776.
60. Grimbergen YA, Roos RA. Therapeutic options for Huntington's disease. Curr Opin Investig Drugs 2003;4: 51-54.
61. Frank SA, Jankovic J. Advances in the pharmacological management of Huntington's Disease. Drugs 2010;70: 561-571.
62. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 2011;11: 1509-1523.
63. Pettibone DJ, Pflueger AB, Totaro JA. Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine. Eur J Pharmacol 1984;102: 431-436.
64. Mehvar R, Jamali F. Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm Sci 1987;76: 461-465.
65. Thibaut F, Faucheux BA, Marquez J, et al. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res 1995;692: 233-243.
66. Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord 2007;22: 10-13.
67. Scherman D, Henry JP. Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol Pharmacol 1984;25: 113-122.
68. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66: 366-372.
69. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48: 358-362.
70. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22: 193-197.
71. Fasano A, Cadeddu F, Guidubaldi A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008;31: 313-318.
72. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol 2009;9: 62.
73. Xenazine. Product information, September 2012. http://www. lundbeck. com/upload/us/files/pdf/Products/Xenazine_PI_US_EN. pdf.
74. Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord 2013;28: 210-215.
75. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984;47: 844-847.
76. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984;9: 329-338.
77. Leonard DP, Kidson MA, Brown JG, Shannon PJ, Taryan S. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust N Z J Psychiatry 1975;9: 115-118.
78. Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988;38: 84-88.
79. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol 2002;25: 263-265.
80. Bonelli RM, Niederwieser G, Tribl GG, Költringer P. High-dose olanzapine in Huntington's disease. Int Clin Psychopharmacol 2002;17: 91-93.
81. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002;105: 441-444.
82. Squitieri F, Cannella M, Piorcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14: 69-72.
83. Dipple HC. The use of olanzapine for movement disorder in Huntington's disease: a first case report. J Neurol Neurosurg Psychiatry 1999;67: 123-124.
84. Cankurtaran ES, Ozalp E, Soygur H, Cakir A. Clinical experience with risperidone and memantine in the treatment of Huntington's disease. J Natl Med Assoc. 2006;98: 1353-1355.
85. Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol 2002;9: 182-183.
86. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Geriatr Psychiatry 1998;6: 347-349.
87. Parsa MA, Szigethy E, Voci JM, Meltzer HY. Risperidone in treatment of choreoathetosis of Huntington's disease. J Clin Psychopharmacol 1997;17: 134-135.
88. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics 2006;47: 70-72.
89. Seitz DP, Millson RC. Quetiapine in the management of psychosis secondary to Huntington's disease: a case report. Can J Psychiatry 2004;49: 413.
90. Bonelli RM, Niederwieser G. Quetiapine in Huntington's disease: a first case report. J Neurol 2002;249: 1114-1115.
91. van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997;63: 35-39.
92. Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatr Dis Treat 2009;5: 1-4.
93. Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24: 126-129.
94. Lin WC, Chou YH. Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease. Am J Psychiatry 2008;165: 1207-1208.
95. Lucetti C, Gambaccini G, Bernardini S, et al. Amantadine in Huntington's disease: open-label video-blinded study. Neurol Sci 2002;23(Suppl. 2): S83-S84.
96. Stewart JT. Adverse behavioral effects of amantadine therapy in Huntington's disease. South Med J 1987;80: 1324-1325.
97. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003;61: 1551-1556.
98. Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007;62: 262-272.
99. Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust 1976;1: 225-227.
100. Frattola L, Albizzati MG, Alemani A, Bassi S, Ferrarese C, Trabucchi M. Acute treatment of Huntington's chorea with lisuride. J Neurol Sci 1983;59: 247-253.
101. Vitale C, Marconi S, Di ML, et al. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: a double blind, randomized cross-over trial. Mov Disord 2007;22: 2359-2364.
102. Corsini GU, Onali P, Masala C, Cianchetti C, Mangoni A, Gessa G. Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor. Arch Neurol 1978;35: 27-30.
103. Low PA, Allsop JL, Halmagyi GM. Huntington's chorea: the rigid form (Westphal variant) treated with levodopa. Med J Aust 1974;1: 393-394.
104. Low PA, Allsop JL. Huntington's chorea-the rigid form (Westphal variant) treated with l-DOPA: a case report. Proc Aust Assoc Neurol 1973;10: 45-46.
105. Magnet MK, Bonelli RM, Kapfhammer HP. Amantadine in the akinetic-rigid variant of Huntington's disease. Ann Pharmacother 2004;38: 1194-1196.
106. Bonelli RM, Niederwieser G, Diez J, Gruber A, Költringer P. Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease. Clin Neuropharmacol 2002;25: 58-60.
107. Groves M, van Duijn E, Anderson K, et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease. PLoS Curr 2011;30: 3.
108. Anderson K, Craufurd D, Edmondson MC, et al. An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington's disease. PLoS Curr 2011;20: 3.
109. www. clinicaltrials. gov. Accessed August 9, 2013.
110. Kieburtz K, McDermott MP, Voss TS, et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol 2010;67: 154-160.
111. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008;65: 1582-1589.
112. Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 2006;18: 553-554.